Bryan Johnson's Blueprint Supplement Stack: What's Worth Taking

What Is Bryan Johnson's Blueprint Protocol?

Bryan Johnson is a tech entrepreneur who sold his company Braintree to PayPal for $800 million in 2013 and then redirected much of his attention — and a reported $2 million per year — toward a personal longevity experiment he calls Project Blueprint. The core premise is simple even if the execution is extreme: treat the human body like a startup, apply rigorous measurement to every biomarker imaginable, and optimize relentlessly based on the data.

Project Blueprint involves daily blood work, continuous glucose monitoring, nightly sleep tracking, MRI and ultrasound scans, and a regimen of over 50 supplements taken at precise times across the day. Johnson publishes his protocols publicly at blueprint.bryanjohnson.co, making the entire stack open-source for anyone curious enough to dig in.

The result is simultaneously fascinating and overwhelming. On one hand, Johnson has achieved measurable biological markers that his team claims are younger than his chronological age — slower epigenetic aging rates, improved VO2 max, and dramatically reduced visceral fat. On the other hand, critics (including many clinicians) point out that the signal-to-noise ratio in his protocol is nearly impossible to interpret. When you're taking 50+ interventions simultaneously, how do you know which ones are working?

This article cuts through the complexity. We'll examine the core Blueprint supplement stack, rank the compounds by clinical evidence quality, flag the ones with genuine scientific backing, and identify the speculative bets that even Johnson himself acknowledges are high-uncertainty. We'll also connect the dots to what personalized supplementation actually looks like when it's grounded in your own lab data rather than someone else's optimized routine.

---

Blueprint Protocol Supplements: The Full Landscape

Johnson's publicly documented supplement list has varied over time but consistently includes several categories. Let's map them out before evaluating individual components.

The Core Daily Stack (Green Zone: Strong Evidence)

The High-Uncertainty Zone (Yellow/Red)

It's worth stating plainly: Johnson's protocol is not a prescription for you. It's a personal experiment conducted on one individual with a team of physicians monitoring him 24/7. Several of the compounds in his high-uncertainty zone — particularly rapamycin, metformin, and 17α-estradiol — are prescription drugs with real side-effect profiles and no established longevity protocols for healthy adults.

---

Bryan Johnson Don't Die: The Philosophy Behind the Stack

Johnson's broader project — increasingly branded under the slogan "Don't Die" — is less about any individual supplement and more about a systems-level approach to health. The idea is that consciousness, performance, and longevity are all downstream of biological optimization, and that humans are systematically bad at self-regulation because our brains evolved in scarcity environments, not abundance environments.

His framing is provocative: he argues that most humans are "self-destructing" through poor sleep, inflammatory diets, and inconsistent health habits, and that applying the discipline of data-driven engineering to the body is the only reliable counter. The supplements are one layer of that system, sitting alongside an extremely regimented diet (roughly 2,250 calories, plant-heavy, with specific macro timing), a consistent sleep schedule targeting 8+ hours, and a structured exercise protocol.

From an evidence standpoint, the most robust interventions in Johnson's stack are not the exotic ones. They're the boring ones: adequate sleep, resistance training, a diet rich in vegetables and omega-3s, and correcting genuine nutritional deficiencies. The supplements enhance that foundation — they don't replace it.

This is an important point for anyone inspired by Blueprint to build their own protocol. The compounds with the deepest clinical evidence are also the most broadly applicable. You don't need Johnson's budget to benefit from well-dosed omega-3s, optimized vitamin D status, or magnesium glycinate at therapeutic levels.

It's also worth understanding why the "Don't Die" framework resonates beyond biohacker circles. Aging research has shifted dramatically in the past decade — from describing aging as an inevitable process to characterizing it as a modifiable biological phenomenon driven by identifiable hallmarks: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication (López-Otín et al., Cell 2013; PMID: 23746838). Blueprint's supplement strategy attempts to address several of these hallmarks simultaneously. The practical problem — which Johnson acknowledges — is that targeting nine hallmarks with 50 compounds makes attribution nearly impossible without controlled trials.

---

Project Blueprint Stack: Ingredient-by-Ingredient Evidence Review

Omega-3 Fatty Acids (EPA/DHA)

This is the clearest example of a supplement with decades of rigorous clinical evidence. Johnson takes high-dose EPA+DHA, and the science supports that approach at meaningful doses.

A landmark meta-analysis published in JAMA Cardiology found that omega-3 supplementation at doses above 1g EPA+DHA per day significantly reduced cardiovascular events, with higher doses showing dose-dependent benefits (Bhatt et al., JAMA Cardiology 2019; doi.org/10.1001/jamacardio.2019.2210). The REDUCE-IT trial specifically demonstrated that 4g/day of EPA (icosapentaenoic acid) reduced major cardiovascular events by 25% compared to placebo in high-risk patients over a median of 4.9 years.

Beyond cardiovascular endpoints, EPA and DHA have well-documented roles in neuroinflammation reduction. A 2020 meta-analysis found that omega-3 supplementation significantly reduced serum levels of IL-6 and TNF-α — key inflammatory cytokines associated with accelerated aging (Calder et al., Nutrients 2020; PMID: 32717965).

One mechanistic detail worth highlighting: EPA and DHA are substrates for specialized pro-resolving mediators (SPMs) — lipid molecules including resolvins, protectins, and maresins that actively turn off inflammatory cascades rather than simply blocking them. This resolution-of-inflammation pathway is distinct from the COX-2 inhibition that NSAIDs use, which is why omega-3s and anti-inflammatory drugs can work through complementary mechanisms. Higher circulating DHA specifically is associated with greater resolvin D-series production, which may explain why whole-food omega-3 sources (where EPA and DHA come packaged together) outperform isolated EPA in some neurological endpoints.

For longevity applications, the anti-inflammatory and lipid-modifying effects of EPA/DHA are probably the most clinically validated in Johnson's entire stack. The evidence supports doses of at least 1–2g EPA+DHA daily for most adults, with higher doses (3–4g) in those with elevated triglycerides or inflammatory markers.

Vitamin D3 + K2 (MK-7)

Vitamin D deficiency affects an estimated 1 billion people globally, and even in non-deficient populations, optimal serum 25(OH)D levels are debated. Johnson targets 25(OH)D levels in the 50–80 ng/mL range — above standard clinical thresholds but within the range some longevity researchers consider optimal.

The co-administration of D3 with K2 in the MK-7 form is mechanistically sound. Vitamin D increases calcium absorption, and K2 (MK-7) directs that calcium toward bone via osteocalcin activation and away from arterial walls via Matrix Gla Protein (MGP) carboxylation. A 2015 randomized controlled trial found that MK-7 supplementation at 180mcg/day for 3 years significantly reduced arterial stiffness in postmenopausal women, with pulse wave velocity — the gold-standard measure of vascular stiffness — decreasing significantly in the MK-7 group but not in placebo (Knapen et al., Thrombosis and Haemostasis 2015; PMID: 25694037).

The K2 MK-7 form is meaningfully superior to MK-4 for supplementation purposes: MK-7's half-life is approximately 72 hours versus MK-4's 1–2 hours, which means MK-7 achieves stable circulating carboxylation activity from a once-daily dose. This matters clinically because undercarboxylated MGP — the inactive form — is a direct marker of arterial calcification risk.

For anyone interested in how supplements interact with cardiovascular and bone health markers, what supplements affect cholesterol ratio provides additional context on lipid-modifying mechanisms.

Magnesium

Johnson uses a combination of magnesium forms, including glycinate and L-threonate. This is clinically intelligent — different magnesium forms have different tissue targets. Glycinate has high bioavailability and excellent tolerability for systemic deficiency correction, while L-threonate has been specifically studied for brain magnesium levels and cognitive applications.

A 2022 study in the European Journal of Nutrition found that magnesium deficiency accelerates DNA damage accumulation and is inversely associated with telomere length — a key biomarker of cellular aging (Maier et al., European Journal of Nutrition 2022; PMID: 35882649). Given that dietary surveys consistently show 50–70% of Americans fall below the Recommended Dietary Allowance for magnesium, this is one supplement where population-wide deficiency makes broad supplementation defensible.

Magnesium also plays a central role in insulin sensitivity, with over 300 magnesium-dependent enzymatic reactions involved in glucose metabolism. This aligns with Johnson's broader metabolic optimization goals. Clinically, studies in hypomagnesemic diabetic patients show that oral magnesium supplementation at 382mg/day for 16 weeks improved both fasting glucose and HbA1c — independent of changes in diet or medication (Rodríguez-Morán and Guerrero-Romero, Diabetes Care 2003; PMID: 12610012). That effect size may not translate identically to magnesium-replete individuals, but in anyone with confirmed low status, the metabolic dividend is real.

CoQ10 / Ubiquinol

CoQ10 is a mitochondrial electron transport chain component and lipid-soluble antioxidant. Johnson's use of it makes physiological sense: mitochondrial function declines with age, and CoQ10 synthesis decreases in parallel. Statin users have a particularly strong case for supplementation, as statins inhibit the same mevalonate pathway used to synthesize endogenous CoQ10.

A meta-analysis in Antioxidants found that CoQ10 supplementation significantly reduced plasma malondialdehyde (a marker of lipid peroxidation) and increased superoxide dismutase activity — both markers of reduced oxidative stress (Fan et al., Antioxidants 2017; PMID: 29135907). The ubiquinol form is generally considered superior to ubiquinone for bioavailability, particularly in older adults whose intestinal conversion capacity is reduced.

One clinical nuance: CoQ10 is fat-soluble, meaning absorption increases meaningfully when taken with a meal containing dietary fat — Johnson's plant-heavy diet includes sufficient healthy fats to facilitate this. For anyone taking ubiquinol in isolation without fat co-ingestion, bioavailability can drop by 30–50% compared to fed-state absorption. Newer liposomal and emulsified formulations partially close this gap, but the simplest intervention remains taking it with food.

For longevity applications, CoQ10 at 200mg ubiquinol is a clinically reasonable dose with a solid safety profile and meaningful mechanistic support.

Ashwagandha (KSM-66)

Johnson's protocol includes ashwagandha, and the specific form matters here. KSM-66 is a full-spectrum root extract standardized to 5% withanolides with the strongest clinical evidence base among ashwagandha preparations.

A 60-day randomized, double-blind, placebo-controlled trial found that KSM-66 at 600mg/day significantly reduced serum cortisol (by 27.9%), perceived stress scores, and anxiety levels compared to placebo in chronically stressed adults (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). Separately, a study in the American Journal of Men's Health found that 600mg/day of KSM-66 for 8 weeks significantly increased testosterone levels (+14.7%) and muscle recovery markers in resistance-trained men.

For high-performers managing chronic stress alongside intense physical training — as Johnson does — KSM-66 addresses multiple downstream pathways simultaneously: HPA axis regulation, testosterone support, and muscle recovery.

The cortisol-lowering mechanism is particularly relevant to longevity. Chronically elevated cortisol accelerates hippocampal atrophy, suppresses immune function, promotes visceral fat deposition, and worsens insulin sensitivity — all pathways that compound aging risk. Addressing HPA dysregulation with a well-dosed adaptogen is therefore not merely about stress relief; it's about interrupting a downstream cascade that touches multiple aging hallmarks simultaneously.

Lycopene and Lutein/Zeaxanthin

These carotenoids represent a class of compounds where Johnson's protocol overlaps with well-established evidence in specific tissue protection — prostate and macular health, respectively.

Lycopene at 10–20mg daily has been associated with reduced prostate cancer risk and improved endothelial function in multiple observational and intervention studies. Lutein and zeaxanthin at 10–20mg are the only dietary compounds known to accumulate in the macula and filter high-energy blue light, with the AREDS2 trial demonstrating meaningful protection against age-related macular degeneration progression in high-risk individuals. These are not exotic longevity compounds — they're clinically validated for specific tissue targets with decades of supporting evidence.

Lycopene also deserves mention for its LDL oxidation protection. Oxidized LDL — not LDL particle count per se — is the atherogenic species that initiates foam cell formation and plaque development. Lycopene inhibits LDL oxidation through its singlet oxygen quenching capacity, which is roughly ten times greater than beta-carotene on a molar basis. This positions it as a useful complement to omega-3s in a comprehensive cardiovascular protection strategy.

---

Bryan Johnson Rapamycin: The Most Controversial Element

Of everything in Johnson's stack, rapamycin generates the most scientific debate — and for good reason. Rapamycin (sirolimus) is an FDA-approved immunosuppressant used in organ transplant patients. It works by inhibiting mTOR (mechanistic Target of Rapamycin), a central cellular signaling hub that regulates growth, metabolism, autophagy, and aging.

The scientific rationale is genuinely compelling. mTOR inhibition has extended lifespan in every model organism studied — yeast, worms, flies, and mice — with some mouse studies showing 25–40% lifespan extensions even when rapamycin was started late in life (Harrison et al., Nature 2009; PMID: 19587680). The ITP (Interventions Testing Program), a rigorous multi-site NIA-funded program, has replicated this effect in genetically diverse mouse populations multiple times.

Johnson takes a low, intermittent dose — reportedly 13mg once weekly — which is different from the continuous high doses used in transplant immunosuppression. The rationale for intermittent dosing is to capture the mTOR-inhibition benefits while minimizing immunosuppressive and metabolic side effects (rapamycin can impair glucose metabolism and wound healing at sustained doses). mTORC1 and mTORC2 are inhibited differentially at different doses and exposure durations — mTORC1 is the autophagy-promoting target, while sustained mTORC2 inhibition is associated with insulin resistance. Intermittent dosing is a pharmacological attempt to hit mTORC1 while allowing mTORC2 to recover between doses.

However, there is no randomized controlled trial demonstrating lifespan or healthspan extension in healthy humans. The translation from mouse models to humans is far from guaranteed — many interventions that extend mouse lifespan have failed to translate. The side-effect profile in healthy individuals over multi-year use is unknown.

What do leading longevity researchers say? The field is genuinely split. Some researchers are cautious about human use given the immunosuppressive risks. Others, like Matt Kaeberlein at the University of Washington, are running the first systematic study of rapamycin in healthy middle-aged humans (the PEARL trial) — a clear sign the scientific community takes the hypothesis seriously enough to test it rigorously. Results from PEARL are expected to provide the first controlled human data on safety and biomarker effects, though the trial is not powered to detect lifespan changes.

Bottom line: rapamycin is a high-risk, high-potential bet that no evidence-based clinician can recommend for healthy adults in 2024. Johnson takes it with full physician oversight, regular immune function monitoring, and complete acknowledgment that he is running an n=1 experiment.

---

NMN, NR, and NAD+ Precursors: Promising or Premature?

Johnson takes NMN (nicotinamide mononucleotide), one of several NAD+ precursor compounds that have generated enormous excitement in longevity research. NAD+ (nicotinamide adenine dinucleotide) declines with age and is essential for sirtuins — a family of proteins involved in DNA repair, mitochondrial biogenesis, and metabolic regulation.

The animal data is striking: restoring NAD+ levels in aged mice has improved muscle function, metabolic health, and in some cases extended lifespan. Human trials are now emerging. A 2021 randomized clinical trial found that NMN supplementation at 250mg/day for 10 weeks increased blood NAD+ levels and improved muscle insulin sensitivity in older women (Yoshino et al., Science 2021; PMID: 34347572). This is meaningful but modest — muscle insulin sensitivity is not the same as longevity.

Critically, the question of whether supplemental NMN or NR actually reaches tissues and meaningfully raises NAD+ in humans is still being worked out. Some studies show blood NAD+ increases; whether that translates to cellular and mitochondrial NAD+ restoration is less clear. There's also an important distinction between the two precursors: NR (nicotinamide riboside) must be converted to NMN before entering cells, while NMN can enter certain cell types more directly — though the relative efficiency of these pathways in different human tissues remains an active research question. At this stage, NMN and NR should be considered investigational longevity tools rather than validated supplements.

This is an area where the science is genuinely exciting and genuinely early. If you're building a personalized supplement protocol, NAD+ precursors are worth watching — but they're not the first-line evidence-based priority that omega-3s or magnesium correction represent.

---

Spermidine and Autophagy Induction

Spermidine is a naturally occurring polyamine found in foods like wheat germ, soybeans, and aged cheese. Johnson includes it for its purported ability to induce autophagy — the cellular self-cleaning process that clears damaged proteins and organelles, and which is increasingly implicated in longevity.

Observational data from large epidemiological studies in Europe found that higher dietary spermidine intake was associated with reduced all-cause mortality (Kiechl et al., American Journal of Clinical Nutrition 2018; PMID: 29992272). A small pilot RCT in older adults with subjective cognitive decline found that spermidine supplementation at 1.2mg/day for 12 months improved memory performance compared to placebo, though the sample was small (n=85).

The autophagy rationale is biologically sound — spermidine activates autophagy through mechanisms that overlap with but are distinct from caloric restriction. Specifically, spermidine inhibits the acetyltransferase EP300, leading to deacetylation of autophagy-initiating proteins including ATG7 and LC3 — a pathway that doesn't require mTOR inhibition and therefore can work additively with rapamycin-like compounds. The human evidence is preliminary, with larger trials needed to confirm the memory and longevity signals seen in smaller studies.

---

What's Actually Worth Taking From the Blueprint Stack

Here's an honest ranking of the Blueprint compounds by evidence quality and practical applicability for most adults:

Tier 1: Take These (Strong Evidence, Low Risk)

1. Omega-3 EPA/DHA — 2–4g/day from high-quality fish or algae oil. Cardiovascular, anti-inflammatory, and neurological benefits are among the most replicated in supplement science.
2. Vitamin D3 + K2 (MK-7) — Correct to adequate 25(OH)D status (most labs target 40–60 ng/mL). Add MK-7 at 100–200mcg for cardiovascular safety.
3. Magnesium — Most adults are deficient. Glycinate for systemic correction, L-threonate if cognitive application is the goal.
4. CoQ10/Ubiquinol — Particularly important for adults over 40, statin users, or anyone with mitochondrial concerns. 100–200mg ubiquinol is a clinically defensible dose.

Tier 2: Consider Based on Individual Labs and Goals

1. Ashwagandha KSM-66 — If you have elevated cortisol, poor HRV, disrupted sleep, or suboptimal testosterone, the clinical evidence is solid at 600mg/day.
2. Zinc — Essential if dietary intake is suboptimal or if you have elevated CRP (zinc is acutely depleted during inflammatory states). Even borderline low zinc impairs T-cell proliferation, making immune surveillance less efficient — a relevant aging concern independent of acute illness.
3. Lycopene/Lutein — Particularly valuable for men concerned about prostate health and anyone with macular degeneration risk factors.

Tier 3: Watch the Science (Promising but Early)

1. NMN/NR — Biologically compelling. Human evidence is emerging but insufficient to make it a cornerstone supplement at current evidence levels.
2. Spermidine — Epidemiological signal is interesting; intervention trials too small to base protocol decisions on yet.

Tier 4: Not for DIY Use (Prescription or Very High Uncertainty)

1. Rapamycin — Compelling animal data; no human RCT evidence for longevity in healthy adults; meaningful side-effect profile.
2. Metformin, Acarbose — Prescription drugs with metabolic rationale but not appropriate for self-administration without diagnosis and physician oversight.
3. 17α-estradiol, Epitalon — Essentially zero validated human longevity data.

---

How to Build Your Own Evidence-Based Longevity Stack

The most important takeaway from Johnson's Blueprint is not the specific compounds — it's the principle of data-driven personalization. Johnson optimizes his protocol based on extensive biomarker data. The same principle applies to you, even without a $2 million annual budget.

The starting point is always your own labs. Serum 25(OH)D tells you whether vitamin D supplementation is warranted and at what dose. A full omega-3 index (EPA+DHA as a percentage of red blood cell fatty acids) tells you whether your DHA/EPA status is actually suboptimal or just needs maintenance doses. Serum magnesium is a rough proxy, but red blood cell magnesium is more sensitive. hs-CRP tells you whether an anti-inflammatory intervention is likely to show meaningful results.

Without that data, you're essentially running your own n=1 experiment with no baseline — spending money on supplements that may be unnecessary for your specific physiology while potentially missing deficiencies that are actually causing symptoms.

A practical sequencing approach: begin with the highest-leverage, lowest-risk interventions — the Tier 1 compounds — and run labs at 90-day intervals to confirm directional movement in your target biomarkers. If serum 25(OH)D doesn't respond to 2,000 IU D3, you may have a VDR polymorphism or malabsorption issue that warrants investigation before simply escalating the dose. If omega-3 supplementation at 2g/day doesn't move your omega-3 index after 12 weeks, absorption — not dose — may be the limiting factor, and switching to a triglyceride-form omega-3 or a phospholipid-bound krill formulation could be worth evaluating.

For building a thoughtful supplement stack without creating dangerous interactions, the supplement stacking guide for combining supplements safely provides a framework for sequencing and pairing correctly.

For those dealing with insulin resistance — a key longevity risk factor that Johnson's protocol aggressively addresses — supplements for insulin resistance with clinical trial backing provides evidence-based options aligned with actual clinical data.

And if weight management is part of your longevity equation, whether a weight loss supplement stack is worth taking based on clinical trials offers a grounded analysis of what actually works versus what's marketing.

The PQQ supplement clinical trials review is also relevant here — PQQ (pyrroloquinoline quinone) targets mitochondrial biogenesis through PGC-1α activation, a pathway adjacent to what CoQ10 and NAD+ precursors address, and it appears in some longevity-oriented stacks as a complement to ubiquinol.

---

What This Means for Your Formula

Ones was built on the same core principle that underlies Johnson's project: supplements should be personalized to what your biology actually shows, not to what works for someone else. Where Ones and Blueprint diverge is in accessibility and risk profile. Ones uses your blood work, wearable data, and health history to build a custom capsule formula from a catalog of ~70 clinically validated ingredients — without the prescription compounds, the $2 million budget, or the need for a personal physician team.

Several compounds from Blueprint's Tier 1 list are central to Ones formulas, dosed to match clinical evidence:

Omega-3 (EPA/DHA): Ones includes pharmaceutical-grade omega-3 dosed based on your omega-3 index and cardiovascular risk profile. If your hs-CRP is elevated or your triglycerides are high, the formula calibrates accordingly — rather than defaulting to a one-size-fits-all dose.

CoQ10/Ubiquinol at 200mg: Ones includes ubiquinol at 200mg — the dose shown in clinical trials to meaningfully reduce markers of oxidative stress. This is particularly relevant for users whose wearable data shows low HRV or whose labs suggest mitochondrial stress patterns.

Ashwagandha KSM-66 at 600mg: When your cortisol markers, HRV trends, or testosterone levels indicate HPA axis dysregulation, Ones incorporates KSM-66 at the 600mg dose used in Chandrasekhar's 2012 trial. This is meaningfully different from low-dose ashwagandha in generic multi-ingredient blends that don't reach therapeutic levels.

Ones also includes its proprietary Adrenal Support and Endocrine Support System Blends, which address the same stress-hormone and hormonal-health axes that Johnson's protocol targets — but through a formulation calibrated to your specific biomarker picture rather than a generalized longevity bet.

The goal isn't to replicate Blueprint. It's to take the data-driven philosophy that makes Blueprint compelling and apply it to your actual biology at a scale that works for real people.

---

Key Takeaways

• Bryan Johnson's Blueprint stack spans 50+ compounds, ranging from rock-solid evidence (omega-3s, vitamin D3+K2, magnesium) to high-risk prescription drugs (rapamycin, metformin) with no validated human longevity data.
• Tier 1 compounds — omega-3 EPA/DHA, D3+K2, magnesium, and CoQ10/ubiquinol — are the most evidence-backed and broadly applicable elements of the stack, regardless of age or health status.
• Rapamycin shows genuinely compelling animal data for lifespan extension via mTOR inhibition, but no RCT evidence exists for healthy humans, and the side-effect profile makes it unsuitable for unsupervised use.
• NAD+ precursors (NMN/NR) and spermidine are scientifically interesting but remain early-stage interventions — worth watching, not worth betting your supplement budget on in 2024.
• The most transferable insight from Blueprint is not the compounds but the method: start with your own labs, identify what your biology actually needs, and dose to clinical ranges rather than to proprietary blend minimums.
• Personalized, lab-informed supplementation — the approach used by platforms like Ones — captures the data-driven philosophy of Blueprint without the experimental risk, the prescription drug exposure, or the $2 million price tag.

---

This article is for informational purposes only. Several compounds discussed — including rapamycin, metformin, and acarbose — are prescription medications. Nothing here constitutes medical advice. Consult a qualified healthcare provider before making changes to your supplement or medication regimen.